Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1Unknown 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 358Precursor Cell Lymphoblastic Leukemia-Lymphoma 164Leukemia 160Lymphoma 109Myelodysplastic Syndromes 74Lymphoma, Non-Hodgkin 66Lymphoma, Large B-Cell, Diffuse 61Lymphoma, Mantle-Cell 59Burkitt Lymphoma 58Recurrence 56Congenital Abnormalities 44Leukemia, Monocytic, Acute 39Lymphoma, Follicular 37Hodgkin Disease 35Leukemia, Myelomonocytic, Acute 34Leukemia, Erythroblastic, Acute 34Leukemia, Megakaryoblastic, Acute 32Blast Crisis 29Lymphoma, Large-Cell, Immunoblastic 27Leukemia, Myelomonocytic, Chronic 26Leukemia, Lymphocytic, Chronic, B-Cell 26Leukemia, Biphenotypic, Acute 26Leukemia, Myelogenous, Chronic, BCR-ABL Positive 24Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, B-Cell, Marginal Zone 19Anemia, Refractory, with Excess of Blasts 19Myeloproliferative Disorders 17Lymphoma, B-Cell 17Leukemia, Myeloid, Accelerated Phase 16Neoplasm, Residual 15

Interventions

pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Carboplatin 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Cytarabine × Clear all
NCT01656252 2020-11-03

PrE0901

PrECOG, LLC.

Phase 1/2 Terminated
15 enrolled 5 charts
Classical hematologyOther hematologic neoplasm

Jacobs syndrome, Pathologic Complete Response, Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Nanfang Hospital, Southern Medical University

Phase 2 Unknown
100 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT01843179 2017-02-17

Sulindac for Patients With AML

Massachusetts General Hospital

Phase 2 Withdrawn
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡